M. Sieber

发表

Molecular-epidemiological aspects of carcinogenesis : the role of xenobiotic metabolizing enzymes *

V. Diehl, H. Tesch, U. Fuhr, 2002 .

Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.

R. Greil, R. Müller, N. Willich, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Dirk Hasenclever, Peter Koch, Markus Sieber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

H. Eich, R. Müller, S. Sehlen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Advanced Stage Hodgkin’s Disease

V. Diehl, H. Tesch, M. Sieber, 2001, Oncology.

Spleen involvement in Hodgkin's lymphoma: assessment and risk profile

M. Sieber, A. Gossmann, A. Josting, 2003, Annals of Hematology.

Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.

H. Eich, R. Müller, V. Diehl, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease – Results of the German Hodgkin Study Group

V. Diehl, J. Franklin, M. Sieber, 2005, Leukemia & lymphoma.

Low-Dose Radiat ion Is Sufficient for the Noninvolved

R. Greil, R. Müller, N. Willich, 2001 .

Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Sieber, U. Rüffer, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Hodgkin's disease - new treatment strategies toward the cure of patients.

V. Diehl, M. Sieber, A. Jox, 1999, Cancer treatment reviews.

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease

M. Pfreundschuh, D. Hasenclever, H. Tesch, 1995 .

Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1114 patients

V. Diehl, L. Braitman, M. Sieber, 2005, Leukemia & lymphoma.

7b Treatment of intermediate stages

V. Diehl, H. Tesch, M. Sieber, 1996 .

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.

V. Diehl, M. Sieber, F. Morschhauser, 2003, Blood.

Treatment of relapsed CD 20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated : results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

V. Diehl, M. Sieber, T. Rüdiger, 2002 .

Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.

V. Diehl, J. Franklin, M. Sieber, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary M yeloid L eukemia a nd M yelodysplastic S yndromes in P atients T reated f or H odgkin's D isease: A R eport F rom t he German H odgkin's L ymphoma S tudy G roup

V. Diehl, J. Franklin, J. Wolf, 2003 .

Biology, Staging and Treatment of Hodgkin’s Disease

V. Diehl, H. Tesch, M. Sieber, 1995 .

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.

R. Greil, V. Diehl, J. Franklin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.

V. Diehl, B. Lathan, H. Tesch, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG.

V. Diehl, H. Tesch, M. Sieber, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection.

V. Diehl, M. Sieber, B. Salzberger, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

V. Diehl, N. Schmitz, J. Franklin, 1998, Blood.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Dirk Hasenclever, Markus Sieber, Norbert Schmitz, 2002, The Lancet.

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, J. Wolf, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

V. Diehl, B. Dörken, M. Sieber, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.

V. Diehl, J. Franklin, M. Sieber, 2000, Blood.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG).

V. Diehl, B. Lathan, M. Sieber, 2003, European journal of cancer.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

V. Diehl, B. Dörken, M. Sieber, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.

V. Diehl, H. Gerhartz, J. Franklin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study Group Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Prognostic factors and treatment outcome in primary progressive

V. Diehl, J. Franklin, M. Sieber, 2013 .

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

V. Diehl, J. Franklin, M. Pfreundschuh, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).

V. Diehl, M. Pfreundschuh, D. Hasenclever, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Sieber, A. Engert, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.

V. Diehl, M. Pfreundschuh, B. Lathan, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group.

V. Diehl, M. Sieber, M. Henry-Amar, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.

R. Greil, N. Willich, V. Diehl, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

M Sieber, A Engert, H. Eich, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The HD12 Panel of the German Hodgkin Lymphoma Study Group (GHSG): A Quality Assurance Program Based on a Multidisciplinary Panel Reviewing All Patients’ Imaging

H. Eich, R. Müller, V. Diehl, 2004, American journal of clinical oncology.

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

M. Bangerter, A. Hinke, V. Heinemann, 2011, BMC Cancer.

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease

V. Diehl, H. Gerhartz, K. Hübner, 1998 .

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

M. Sieber, J. Glossmann, B. Metzner, 2004 .